Role of Tyrosine Kinase Inhibitor (TKI) in stage IV adenocarcinoma of lung: Early outcome from tertiary cancer hospital.

Authors

  • Manoj Tiwari Thoracic Unit, Dept of Surgical Oncology B P Koirala Memorial Cancer Hospital, Bharatpur, Nepal
  • Binay Thakur Thoracic Unit, Dept of Surgical Oncology B P Koirala Memorial Cancer Hospital, Bharatpur, Nepal
  • Sagar Khatiwada Thoracic Unit, Dept of Surgical Oncology B P Koirala Memorial Cancer Hospital, Bharatpur, Nepal
  • Sachee Bhattarai Thoracic Unit, Dept of Surgical Oncology B P Koirala Memorial Cancer Hospital, Bharatpur, Nepal

DOI:

https://doi.org/10.3126/njc.v9i2.84922

Keywords:

TKI, EGFR, adeno carcinoma, targeted therapy

Abstract

Background: Adenocarcinoma of lung is the most common type of non-small cell lung cancer. Driver mutation, especially EGFR mutation is not uncommon and tyrosine kinase inhibitor (TKI) is the mainstay treatment for stage IV disease. We aim to evaluate early outcome and progression free survival (PFS) of TKI with stage IV adenocarcinoma in Nepal.

Methods: A prospective observational study was carried out in 20 patients with stage IV adenocarcinoma harboring mutations (EGFR, ALK, ROS-1). Clinicodemographic details, molecular status, type of TKI  PFS and survival outcomes were analyzed.

Results: A total of 20 patients were included. The mean age was 57.4 years (range 31–76); 60% were female, and 75% were smokers. EGFR exon 19 deletion was the most frequent mutation (70%), followed by exon 21 (25%). Osimertinib was prescribed to 55% of patients, gefitinib to 40%, and crizotinib to 5%. At 2 years, overall survival was 78%, PFS was with a median survival of 14.6 months.

Conclusion: TKIs demonstrated promising short-term survival outcomes in stage IV adenocarcinoma lung within the Nepalese population. Continued follow-up and larger cohorts are needed to define long-term outcomes and resistance mechanisms in this setting.

Downloads

Download data is not yet available.
Abstract
24
PDF
8
Cover NJC

Downloads

Published

2025-09-30

How to Cite

Tiwari, M., Thakur, B., Khatiwada, S., & Bhattarai, S. (2025). Role of Tyrosine Kinase Inhibitor (TKI) in stage IV adenocarcinoma of lung: Early outcome from tertiary cancer hospital. Nepalese Journal of Cancer, 9(2), 53–57. https://doi.org/10.3126/njc.v9i2.84922

Issue

Vol. 9 No. 2 (2025)

Section

Original Articles

License

Copyright (c) 2025 Nepalese Journal of Cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as NJC and the authors are acknowledged.

Submission of the manuscript means that the authors agree to assign exclusive copyright to NJC. The aim of NJC is to increase the visibility and ease of use of open access scientific and scholarly articles thereby promoting their increased usage and impact.